United States: Teva And Alvotech's Adalimumab Biosimilar Receives Interchangeable Status At FDA - Goodwin Procter LLP

On February 23rd, 2024, Alvotech and Teva announced FDA's approval of SIMLANDI (adalimumab-ryvk), the first high-concentration and citrate-free biosimilar interchangeable with Humira...